Correspondence and offprint requests to: Geoffrey Douglas Braatvedt; E-mail: g.braatvedt@auckland.ac.nz Abstract Background. In this study, our main goal was to determine whether an integrated, community-based model of care using culturally appropriate health-care assistants to manage hypertension in Māori and Pacific patients with diabetes and chronic kidney disease (CKD) is more effective than conventional care in achieving blood pressure (BP) targets and delaying progression of cardiac and renal end-organ damage.
18. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. A community-based model of care improves blood pressure control and delays progression of proteinuria, left ventricular hypertrophy and diastolic dysfunction in Māori and Pacific patients with type 2 diabetes and chronic kidney disease: a randomized controlled trial
Methods. Sixty-five Māori and Pacific patients (aged 47-75 years) with type 2 diabetes, moderate CKD (>0.5 g proteinuria/day, serum creatinine 130-300 μmol/l) and hypertension were randomized to usual care (n = 32) or community/intervention care (n = 33) for 12 months. Community care patients were visited monthly by a nurse-led health-care assistant for BP measurement. Antihypertensives were adjusted using a stepwise protocol, aiming for a BP <130/80 mmHg. Office BP and renal and echocar
Introduction
Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD) in New Zealand, particularly in Māori and Pacific people [1] who additionally have an increased mortality compared with non-Māori with ESRD [2, 3] . Hypertension occurs in the majority of patients CKD and plays an important role in the progression of diabetic nephropathy to ESRD [4] . Structural and functional cardiac abnormalities such as left ventricular hypertrophy (LVH) and LV diastolic dysfunction are the common findings in patients with diabetes and hypertension [5, 6] , and predict myocardial infarction, stroke and cardiovascular death [7] [8] [9] . Independent of this, stage 3 [estimated glomerular filtration rate (eGFR) 30-59 ml/min/1.73 m 2 ] and stage 4 (eGFR 15-29 ml/min/1.73 m 2 ) CKD and albuminuria are important predictors of cardiac morbidity and mortality [10, 11] . Effective BP control in patients with diabetes has been shown in randomized controlled studies to lead to a delay in progression of CKD, LVH and diastolic dysfunction [12] .
Despite the above evidence, target BP in patients with CKD and diabetes is infrequently achieved [13] . In contrast, alternative models of health-care delivery for BP control, such as nurse-led hypertension clinics [14, 15] and collaborative, community-based programmes using community health-care workers [16] , have been shown to be more effective than conventional approaches in lowering BP and reducing cardiovascular risk.
Materials and methods
We conducted a randomized controlled trial (DEFEND-DElay Future End-stage Nephropathy due to Diabetes) to determine whether a novel model of care involving monthly community visits by a nurse-led, culturally appropriate Māori or Pacific health-care assistant (HCA) is more effective than conventional care in improving BP control, and as a consequence would limit kidney and cardiac disease progression in Māori and Pacific patients with diabetic kidney disease and hypertension.
Patients were screened and recruited through the hospital diabetes and renal clinics and primary care practices in two areas of Auckland, which provides comprehensive public health care for a population of about 900 000. The study was approved by the local ethics committee and received approval by the respective Māori and Pacific Island Health Services in the community and hospital. Patients provided written, informed consent, using an interpreter when required. This trial is registered with the Australian and New Zealand Clinical Trials Registry (ACTRN12605000112662).
Inclusion criteria were Māori and Pacific patients with type 2 diabetes, aged 40-75 years, with diabetic nephropathy (>0.5 g proteinuria/24-h and serum creatinine 130-300 μmol/l) and BP >130/80 mmHg. Exclusion criteria included insulin dependence within 12 months of diagnosis of diabetes, evidence of non-diabetic renal disease and severe chronic illness including malignancy, heart failure, respiratory failure, psychiatric disorder and cognitive impairment.
Two thousand four hundred and thirteen Māori and Pacific patients with type 2 diabetes were screened through the Central Auckland and North Shore diabetes and renal outpatient clinic registers. One thousand eight hundred and twenty-four patients had a serum creatinine and/or 24-h urine protein levels below the threshold for inclusion in the study, while 264 patients had serum creatinine levels >300 μmol/l. Two hundred and fifty-five patients had other significant medical problems to preclude them from entry into the study. Five patients who met the inclusion criteria declined involvement in the study. Sixty-five Māori and Pacific patients meeting the inclusion criteria were randomized into the usual care (n = 32) or community care/intervention (n = 33) groups.
All patients underwent baseline and 12-month visits. At baseline, a detailed medical history was obtained, and a clinical examination was performed on each patient. Information obtained included the duration of diabetes, history of diabetic micro-and macrovascular complications, presence of other cardiovascular risk factors, comorbidities, and current medications. Investigations conducted at baseline and at 12 months included seated office BP, electrocardiography, 2-dimensional (2D) and Doppler echocardiography, serum biochemistry for creatinine, electrolytes, plasma glucose, HbA 1c , lipids and 24-h urine protein collection.
The seated office BP was measured in both arms using an Omron T9P automated BP device. Three measurements were taken at 1-min intervals. The second and third measurements were averaged to give the mean systolic and diastolic BP. Right-sided office BP was the default BP used for data analysis. In cases where the left-sided average systolic BP recordings were significantly higher than the right [n = 1 in the usual care group, n = 3 in conventional care (CC) group], left-sided BP recordings were taken.
A full clinical echocardiogram (Philips HDI 5000/iE33, Bothell, Seattle, WA) was performed at baseline and 12 months [17] . LV geometry (volume and wall thickness) and LA volume were determined and indexed to BSA [17] . LV diastolic function was assessed using mitral valve inflow Doppler with the sample volume between the leaflet tips and tissue Doppler with a 5-mm sample volume on the medial aspect of the mitral valve annulus. The signals were optimized and recorded at 100 mm/s sweep speed. Images were acquired in digital format, and measurements were made at the end of the expiratory phase of normal respiration. All echocardiograms were analysed by one experienced observer (blinded to treatment allocation) using an off-line workstation (Digiview ® , Digisonics, Houston, TX). Each variable was measured in triplicate, and the average of the three measurements was used. LV filling pressure was assessed using the ratio of the peak early mitral inflow velocity (E) to medial mitral annular early diastolic velocity (E'; E/E').
A detailed education package was developed for the study and given to all patients. This focused on diabetes and its complications, the significance of maintaining good BP control, the importance of compliance with medication use, exercise, cessation of smoking, and dietary modification including avoidance of excessive salt intake. At baseline, all patients participated in an individual education session conducted by the research nurse.
The community/intervention group patients were visited monthly by an HCA. Seated BP was measured. Compliance with medication use was checked through a questionnaire. BP results, possible medication side effects, compliance issues and any significant clinical events occurring over the previous month were reported back to the study doctor and nurse. If BP was above target (130/80 mmHg), antihypertensives were changed by the study doctor, in accordance with a stepwise protocol which included an angiotensin-converting enzyme (ACE) inhibitor, a thiazide diuretic, a calcium channel blocker, a beta-blocker and an alpha-blocker if needed. Angiotensin receptor blockers could only be prescribed if the patient was intolerant to ACE inhibitors because of subsidy restrictions in New Zealand. Medication adherence was promoted by feedback on the compliance questionnaire and positive encouragement at the monthly visits.
Patients in the community/intervention group were offered transport if required to their local pharmacy to collect prescribed medications, to their local laboratory for blood and urine tests, and to the follow-up study clinic appointments. These patients continued to also receive routine care from their primary health-care physician and hospital outpatient clinic followup where required. Communication occurred regularly between the DE-FEND trial group and the patient's usual doctors.
The patients in the usual care group, on the other hand, only received routine family doctor and renal/diabetes hospital outpatient clinic care. No attempt was made to alter management of their BP by the DEFEND investigators, and these patients were seen by the study investigators at baseline and 12 months only.
The primary end point of the DEFEND study was a change in office systolic and diastolic BP. Secondary end points included a change in 24-h urine protein excretion, HbA 1c , total cholesterol and any change in cardiac parameters of LV mass/BSA, LA volume/BSA and E/E'.
At the 12-month visit, a record was compiled of clinically significant events that had occurred over the study period. These included death, non-fatal myocardial infarction, new onset of angina, cerebrovascular accident (CVA), heart failure, new onset of symptoms of peripheral vascular disease (PVD), amputation, a vascular procedure (e.g. peripheral angiography), requirement for dialysis and hospitalisation. Medication lists were reviewed. All patients underwent a further clinical examination.
Data were analysed using a mixed model approach to repeated measures. Main effects of treatment allocation and time and their interaction were included in the model. Significant main or interaction effects were further explored using the method of Tukey. P < 0.05 was considered significant. All tests were two-tailed. Normality was assessed using the Shapiro-Wilk's statistic in SAS (version 9.1 SAS Institute, Inc.) as is appropriate for a smaller sample size. The changes from baseline to 12 months for systolic and diastolic blood pressure and for the change in HbA 1c were not significantly distributed from a normal distribution (P = 0.47, 0.89, 0.32, respectively). The change in urine protein to from baseline to 12 months was not normally distributed (P = 0.0083). However, inspection of the plots of the individual data did not suggest an adequate transformation. Accordingly, these data were ranked prior to analysis, and the ranks formed the dependent variable.
This study was originally intended to recruit several hundred participants. However, during recruitment, it was determined that significantly fewer patients would meet the inclusion criteria and thus be eligible for randomization. After inspection of unblinded BP data from the first 30 patients, the principal investigators elected to end recruitment at the end of the calendar year and to continue with a 12-month follow-up period. This resulted in 65 patients being available for randomization. With two groups of 33 and 32 participants, respectively, the study had at least 80% power at the 5% significance level to detect a large (Cohen) treatment effect [69% of 1 standard deviation (SD)].
Results

Baseline characteristics
The ethnic groups represented in the study included patients of Māori, Tongan, Samoan, Cook Island Māori, Niuean and Tuvaluan ethnicity. Both groups were well matched in baseline characteristics ( Table 1 ). The majority of the patients were in stage 3 CKD, and a smaller number were in stage 4 CKD. The mean 24-h urine protein excretion exceeded 3 g (range 0.5-23.2 g/day), and the mean body mass index (BMI) exceeded 35 kg/m 2 . Echocardiographic parameters including LV mass/BSA, LA volume/BSA and E/E' were well matched between the groups (Table 1) . Fifty-four percent of the patients had LVH at baseline [17] . None of the patients had normal LV diastolic function (E/E' and LA volume/BSA elevated). There was no difference between the groups in the number of prescribed antihypertensives at baseline (P = 0.38) ( Table 1) .
The duration of follow-up for both groups was 12 months. One patient from the community care/intervention group required dialysis. Two patients from the community care/intervention group died during the study period, one of metastatic liver cancer (not clinically apparent at recruitment) and the other of cardiac arrest likely secondary to ischaemic heart disease. Four usual care patients were lost to follow-up during the study. One patient from each group underwent coronary bypass grafting, and one from each group had a transient ischaemic attack. No significant differences were seen between the groups in cardiovascular outcomes.
At 12 months, community care/intervention patients were prescribed a significantly greater mean number of antihypertensive medications (P < 0.01) ( Table 2 ). This group achieved a significantly lower office systolic BP at 12 months compared to the usual care group (P = 0.04) ( Figure 1 and Table 2 ). No significant difference in office diastolic BP was seen between the groups at 12 months ( Figure 1 and Table 2 ). The community care/intervention group also achieved a significantly lower 24-h urine protein excretion at 12 months (P = 0.04) ( Figure 2 and Table 2 ). No significant differences were seen between the groups at 12 months for changes in serum creatinine, HbA 1c or total cholesterol ( Table 2) . We examined plots of the change in systolic blood pressure and urine protein from baseline to 12 months (Figure 3) . While for each variable there were some patients who did show a marked change, these patients were not consistent across all variables. Those patients showing the most changes were not necessarily the same, and the correlation (Spearman) between the change in systolic blood pressure from baseline to 12 months and change in urine protein to 12 months was poor (r = −0.15, P = 0.26).
Four patients from the usual care group were lost to follow-up. Assuming a worst-case scenario, we imputed the mean change to 12 months in the community care group and applied that to those subjects with missing data in the usual care group. As anticipated from this overly conservative approach, the P-values for all end points increased (P = 0.11 for change in 24-h urine protein, P = 0.051 for SBP and P = 0.24 for DBP). In the bestcase scenario where the average change in the usual care group was imputed to those usual care patients lost to follow-up, the probabilities were P = 0.033 for change in 24-h urine protein, P = 0.020 for SBP and P = 0.11 for DBP. A third middle-ground scenario is possible where the parameters for the four usual care patients lost to follow-up did not change over the course of the study (the carry forward last visit approach). This scenario yields P = 0.036 for urine protein, P = 0.028 for SBP and P = 0.16 for DBP. Significant echocardiographic differences were seen between the groups at 12 months (Table 2) . LV mass/BSA increased in the usual care group, but did not change in the community care/intervention group (P < 0.05). LA volume/BSA increased in the usual care group, while an improvement was seen in the community care/intervention group (P < 0.05). There was a trend toward reduction in E/E' in this group, although this did not reach statistical significance (P = 0.13).
Discussion
This is the first study to show, in a randomized controlled design, that an integrated model of care using community health-care workers improved BP control in difficult to manage patients with chronic diabetic kidney disease compared with conventional care. This translated into favourable changes in the clinically important risk factors for cardiovascular disease of proteinuria, LV hypertrophy and LV diastolic dysfunction.
In New Zealand, the age-adjusted prevalence of type 2 diabetes in Māori and Pacific people is 5.8% and 10.0%, respectively, compared to 4.3% in European New Zealanders [18] . The prevalence and rates of progression of diabetic nephropathy from the time of diagnosis of diabetes are higher in Māori and Pacific patients in comparison to European New Zealanders [3, 19] . Once diabetic nephropathy is established, patients progress rapidly to ESRD at a mean rate of decline in GFR of 12 ml/min/year, although there is a marked variation with this, dependent on levels of proteinuria and BP [20] . In addition, there is a large burden of cardiovascular disease in these patients. Previously reported encouraging clinical trial results showing delays in kidney and cardiac damage with tight BP control primarily utilizing renin-angiotensin-aldosterone system blockers [12] have not been successfully translated into everyday clinical practice [13, 21] . In New Zealand, as a consequence of both the high incidence of type 2 diabetes in Māori and Pacific people and the failure of effective BP management, the overall prevalence of dialysis in these groups is 2-4-fold higher compared to European New Zealanders [1, 3] . Māori and Pacific patients with diabetes have generally poorer health outcomes than their European counterparts. There are many potential contributory factors. On average, Māori and Pacific patients have poorer blood glucose control, higher BMI, smoking rates and BP, and an increased prevalence of albuminuria [22, 23] . In New Zealand, primary health care is substantially subsidized, and secondary health care is free. Despite this, there are costs associated with chronic disease management including the cost of medication, transport and time lost from employment to attend clinic follow-up. Māori and Pacific people are more likely to have a lower family income with higher demands related to the support of extended families [24] . These factors combined with lower levels of education for many and language barriers, particularly for Pacific people, constitute barriers to effective health care [24] . Physician-related barriers also exist in the treatment of hypertension and include limited time for patient education and communication, cultural misunderstanding, language barriers, infrequent follow-up and acceptance of suboptimal achievement of goal BP [25] .
In patients with diabetes, nurse-led hypertension clinics have been shown to be effective in lowering BP and decreasing future cardiovascular risk compared to those treated through conventional primary care [14] . The effectiveness of these models of care is thought to be due to a higher utilization of antihypertensive medications resulting from a more frequent follow-up, longer appointment times, and a greater adherence by nursing staff to medication protocols and guideline recommendations [14] .
To address the multiple issues faced by Māori and Pacific people with established diabetic kidney disease, we applied a novel model of care characterized by the utilization of a Māori and Tongan HCA providing a culturally appropriate face to clinical care, allowing patients to have a more frequent follow-up in the community, frequent prompting to take their medications and reduced costs to the patient because of home visits. By 12 months, the intervention group was recorded to be taking 48% more antihypertensive medications than the control group and had significantly lower office systolic BP.
This study aimed to show that a reduction in BP was translated into a reduction in the progression of organ damage. Previously, a home-based outreach programme for BP control using a collaborative physician-nurse-community health-care worker approach not only demonstrated achievement of better BP control in an under-served population, but also showed an improvement in LVH [16] . Our baseline data showed that the patients had well-established progressive stage 3 and 4 CKD, 51 of 65 patients had nephrotic-range proteinuria at baseline and all had either significantly raised LV mass or LV diastolic dysfunction. The patients were obese and had significant vascular comorbidity. Despite this, within 12 months, we were able to show a significant reduction in proteinuria in the intervention group. Proteinuria is a surrogate marker for kidney damage, and a reduction in both proteinuria and blood pressure is expected to result in a delay in CKD progression. However, this study was not powered to show that kind of benefit.
We identified 589 patients with significant kidney disease and diabetes among the 2413 Māori and Pacific patients who were screened. We excluded those who had very advanced kidney disease (serum creatinine >300 μmol/l) and those with other significant medical problems. This enabled us to test this intervention in a relatively homogeneous population reducing potential confounders. However, given the simple community-based approach of the intervention, we think it would work for most patients with type 2 diabetes who have diabetic nephropathy, sub-optimally controlled hypertension and advancing CKD.
The intervention utilized in this study prevented the progressive increase in LV mass that was observed in the control group and led to an improved LV diastolic function (as assessed by the improvement in LA volume). There was no difference in cardiovascular events between the treatment groups at 12 months, although the beneficial effects on LV structure and diastolic function seen would suggest that such effects are plausible within a larger study with a longer duration of follow-up.
The findings of this study have fundamental implications for the way in which comprehensive care is provided to patients with CKD and diabetes. While it is essential to search for better medications to delay CKD progression and limit cardiovascular disease, this study highlights the importance of establishing innovative models in healthcare delivery to ensure the optimal utilization of currently available therapies.
